Delivery Order SPE2DB20D1100-SPE2DB25FE4J2
- Not listed
- The Defense Logistics Agency awarded a $1,396.34 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of NovoLog Mix 70-30 FlexPen 3ml insulin pens. This is a firm fixed-price, non-set-aside contract with a completion date of September 10, 2025, and performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency awarded a delivery order valued at $3,541.58 to AmerisourceBergen Drug Corp for the supply of NovoLog Mix 70-30 FlexPen 3mL insulin pens. The contract, issued on August 28, 2025, with an ultimate completion date of August 29, 2025, represents a firm fixed-price delivery order under a competitive procurement with no set-aside designation. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a $2,289.58 delivery order to AmerisourceBergen Drug Corp for NovoLog Mix 70-30 FlexPen 3ML insulin pens on July 22, 2025, with completion expected by July 23, 2025. This firm fixed-price, non-set-aside contract represents a routine pharmaceutical procurement under DLA's Medical Supply Chain operations. The award was issued to AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its headquarters and serves as a...
- The Defense Logistics Agency awarded a delivery order valued at $1,851.03 to AmerisourceBergen Drug Corp for NovoLog Mix 70-30 FlexPen 3ml insulin pens on April 24, 2025. This non-set-aside, competitively awarded contract represents a firm fixed price delivery order with an ultimate completion date of April 25, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This delivery order is...
- The Defense Logistics Agency awarded a $2,217.78 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of NovoLog Mix 70-30 FlexPen 3ml insulin pens. This is a firm fixed price, competitively awarded contract with a completion date of July 21, 2025, and represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $1,036.87 firm fixed price delivery order to AmerisourceBergen Drug Corp for NovoLog Mix 70-30 FlexPen 3mL insulin products on May 6, 2025, with completion scheduled for May 7, 2025. This non-set-aside contract represents a routine pharmaceutical supply delivery under the company's broader federal contracting relationship with the agency. The order will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $1,725.61 to AmerisourceBergen Drug Corp for NovoLog Mix 70-30 FlexPen 3ml insulin pens on August 18, 2025, with completion scheduled for August 19, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $6,299.57 to AmerisourceBergen Drug Corp for the supply of NovoLog Mix 70-30 FlexPen 3ml insulin medication. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by August 20, 2025. The delivery will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,824.80 for NovoLog Mix 70-30 FlexPen 3mL insulin pens on July 30, 2025, with completion targeted for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of NovoLog Mix 70-30 FlexPen 3mL insulin pens, a widely-used combination insulin product for diabetes management. This firm fixed-price delivery order, valued at $1,252.30, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a potential value of $999,999,999.00 through...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE4J2Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,154.30 to AmerisourceBergen Drug Corp for the supply of NovoLog Mix 70-30 FlexPen 3mL insulin pens. This non-set-aside, competitively awarded contract is structured as a firm fixed price delivery order with a completion date of September 4, 2025. The pharmaceutical products will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a major distributor of medications and healthcare solutions. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical supply vehicle that extends through December 2026. The IDC enables AmerisourceBergen to supply a wide range of pharmaceutical products, medical devices, and specialized healthcare commodities to support military healthcare systems and other federal agencies, including the Defense Health Agency and U.S. Coast Guard. The company's demonstrated capability to fulfill federal medical procurement requirements through open competition and its significant contract portfolio underscore its role as a critical vendor for military pharmaceutical supply needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 9/3/25 |